| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | BCL5; LAZ3; BCL6A; ZNF51; ZBTB27 |
| WB Predicted band size | 79 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human BCL6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于BCL6抗体的3篇文献示例(信息基于公开研究归纳，非真实文献，仅供参考)：
1. **文献名称**：*BCL6 Expression in Diffuse Large B-cell Lymphoma: A Comparative Study of Antibody Clones*
**作者**：Antonella Chadburn et al.
**摘要**：比较不同BCL6抗体克隆(如PG-B6p和D8)在DLBCL组织中的染色特异性和敏感性，强调标准化抗体选择对诊断一致性的重要性。
2. **文献名称**：*BCL6 Post-translational Modifications and Antibody Cross-reactivity in Germinal Center B-cells*
**作者**：Laura Pasqualucci et al.
**摘要**：探讨BCL6蛋白磷酸化/泛素化修饰对抗体结合的影响，揭示特定表位抗体在检测功能状态中的局限性。
3. **文献名称**：*BCL6 Antibody-based Detection of Immune Dysregulation in Autoantibody-associated Diseases*
**作者**：George C. Tsokos et al.
**摘要**：利用BCL6抗体分析系统性红斑狼疮(SLE)患者B细胞中BCL6异常表达，关联其与过度活化的生发中心反应。
4. **文献名称**：*Prognostic Value of BCL6 Protein Expression in Follicular Lymphoma: A Multicenter Validation Study*
**作者**：Daisuke Ennishi et al.
**摘要**：通过免疫组化(IHC)验证BCL6高表达与滤泡性淋巴瘤患者生存率的关系，强调抗体标准化判读对临床预后的意义。
(注：以上为模拟内容，实际文献需通过PubMed/Google Scholar检索关键词“BCL6 antibody”、“BCL6 immunohistochemistry”等获取。)
The B-cell lymphoma 6 (BCL6) protein, encoded by the *BCL6* gene, is a transcriptional repressor critical for regulating lymphocyte development and immune responses. It is primarily expressed in germinal center B-cells, where it controls differentiation, class-switch recombination, and somatic hypermutation by suppressing pro-differentiation and DNA damage response genes. Structurally, BCL6 contains a BTB/POZ domain for protein interactions and zinc finger motifs for DNA binding, enabling recruitment of co-repressor complexes to target gene promoters.
BCL6 is a well-characterized oncogene in lymphoid malignancies. Chromosomal translocations, mutations, or dysregulated expression of *BCL6* are linked to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and other B-cell neoplasms. Its oncogenic role involves blocking apoptosis, promoting proliferation, and maintaining germinal center phenotypes, making it a diagnostic and prognostic marker.
BCL6 antibodies are indispensable tools in research and diagnostics. They detect BCL6 expression via immunohistochemistry (IHC), flow cytometry, or Western blot, aiding in lymphoma classification (e.g., distinguishing germinal center vs. non-germinal center DLBCL subtypes). Therapeutic inhibitors targeting BCL6-co-repressor interactions are under investigation, highlighting its clinical relevance. However, BCL6's physiological roles in T-cells and macrophages, such as modulating inflammation, are also areas of active study.
In summary, BCL6 antibodies bridge basic research and clinical practice, enabling insights into B-cell biology and lymphoid cancer diagnostics.
×
